A 10 Patient Case Report on the Impact of Plasmapheresis Upon Neutralizing Factors Against Adeno-associated Virus (AAV) Types 1, 2, 6, and 8

被引:158
作者
Monteilhet, Virginie [1 ]
Saheb, Samir
Boutin, Sylvie [1 ]
Leborgne, Christian [1 ]
Veron, Philippe [1 ]
Montus, Marie-Francoise [1 ]
Moullier, Philippe [1 ,3 ,4 ]
Benveniste, Olivier [2 ]
Masurier, Carole [1 ]
机构
[1] GENETHON, R&D, Immunol Lab, F-91002 Evry, France
[2] Hop La Pitie Salpetriere, Assistance Publ Hop Paris, Fac Med Pierre & Marie Curie, Inst Myol, Paris, France
[3] CHU Hotel Dieu, INSERM, U649, Lab Therapie Gen, Nantes, France
[4] Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL USA
关键词
HERPES-SIMPLEX VIRUS; HUMAN GENE-THERAPY; SKELETAL-MUSCLE; FACTOR-IX; HEMOPHILIA-B; LIFE-SPAN; VECTORS; MICE; TRANSDUCTION; EXPRESSION;
D O I
10.1038/mt.2011.108
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Adeno-associated viruses (AAV) are small, nonenveloped single-stranded DNA viruses which require helper viruses to facilitate efficient replication. These recombinant viruses are some of the most promising candidates for therapeutic gene transfer to treat many genetic and acquired diseases. Nevertheless, the presence of humoral responses to the wild-type AAV common among humans is one of the limitations of in vivo transduction efficacy in humans using cognate recombinant vector. In this study, based on the serum samples that we were able to collect from various clinical situations, we studied the impact of one to five plasmapheresis (PP), at 1-5 day intervals on neutralizing factor (NAF) titers specific for AAV types 1, 2, 6, and 8 in seropositive patients with diverse pathologies and immunosuppressor treatments. We show that frequent sessions of PP result in drastic reduction of NAF specific for AAV1, 2, 6, and 8 to undetectable levels or titers <1:5, mainly when initial titers, i.e., before the first PP were <= 1:20. Altogether, these results show that the use of PP and its possible association with pharmacological immunosuppressive treatments may help to design optimal management of seropositive patients for AAV gene therapy treatments.
引用
收藏
页码:2084 / 2091
页数:8
相关论文
共 37 条
[1]   Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD) [J].
Athanasopoulos, T ;
Graham, IR ;
Foster, H ;
Dickson, G .
GENE THERAPY, 2004, 11 (Suppl 1) :S109-S121
[2]   Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors [J].
Boutin, Sylvie ;
Monteilhet, Virginie ;
Veron, Philippe ;
Leborgne, Christian ;
Benveniste, Olivier ;
Montus, Marie Francoise ;
Masurier, Carole .
HUMAN GENE THERAPY, 2010, 21 (06) :704-712
[3]   Worldwide Epidemiology of Neutralizing Antibodies to Adeno-Associated Viruses [J].
Calcedo, Roberto ;
Vandenberghe, Luk H. ;
Gao, Guangping ;
Lin, Jianping ;
Wilson, James M. .
JOURNAL OF INFECTIOUS DISEASES, 2009, 199 (03) :381-390
[4]   Recombinant adeno-associated virus type 2, 4, and 5 vectors: Transduction of variant cell types and regions in the mammalian central nervous system [J].
Davidson, BL ;
Stein, CS ;
Heth, JA ;
Martins, I ;
Kotin, RM ;
Derksen, TA ;
Zabner, J ;
Ghodsi, A ;
Chiorini, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (07) :3428-3432
[5]   HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ACTIVATES THE CLASSICAL PATHWAY OF COMPLEMENT BY DIRECT C1-BINDING THROUGH SPECIFIC SITES IN THE TRANSMEMBRANE GLYCOPROTEIN-GP41 [J].
EBENBICHLER, CF ;
THIELENS, NM ;
VORNHAGEN, R ;
MARSCHANG, P ;
ARLAUD, GJ ;
DIERICH, MP .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 174 (06) :1417-1424
[6]   Adeno-associated viruses undergo substantial evolution in primates during natural infections [J].
Gao, GP ;
Alvira, MR ;
Somanathan, S ;
Lu, Y ;
Vandenberghe, LH ;
Rux, JJ ;
Calcedo, R ;
Sanmiguel, J ;
Abbas, Z ;
Wilson, JM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (10) :6081-6086
[7]   Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy [J].
Gao, GP ;
Alvira, MR ;
Wang, LL ;
Calcedo, R ;
Johnston, J ;
Wilson, JM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (18) :11854-11859
[8]   rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice [J].
Gregorevic, Paul ;
Allen, James M. ;
Minami, Elina ;
Blankinship, Michael J. ;
Haraguchi, Miki ;
Meuse, Leonard ;
Finn, Eric ;
Adams, Marvin E. ;
Froehner, Stanley C. ;
Murry, Charles E. ;
Chamberlain, Jeffrey S. .
NATURE MEDICINE, 2006, 12 (07) :787-789
[9]   GLYCOPROTEIN-C OF HERPES-SIMPLEX VIRUS TYPE-1 PREVENTS COMPLEMENT-MEDIATED CELL-LYSIS AND VIRUS NEUTRALIZATION [J].
HARRIS, SL ;
FRANK, I ;
YEE, A ;
COHEN, GH ;
EISENBERG, RJ ;
FRIEDMAN, HM .
JOURNAL OF INFECTIOUS DISEASES, 1990, 162 (02) :331-337
[10]   Preexisting Immunity and Low Expression in Primates Highlight Translational Challenges for Liver-directed AAV8-mediated Gene Therapy [J].
Hurlbut, Gregory D. ;
Ziegler, Robin J. ;
Nietupski, Jennifer B. ;
Foley, Joseph W. ;
Woodworth, Lisa A. ;
Meyers, Elizabeth ;
Bercury, Scott D. ;
Pande, Nilesh N. ;
Souza, David W. ;
Bree, Mark P. ;
Lukason, Michael J. ;
Marshall, John ;
Cheng, Seng H. ;
Scheule, Ronald K. .
MOLECULAR THERAPY, 2010, 18 (11) :1983-1994